Nafamostat
1
Reactions 630 - 7 Dec 1996 ★ S Nafamostat First report of an anaphylactoid reaction: case report An anaphylactoid reaction occurred in a 53-year-old woman after she received nafamostat [Futhan ® ; dosage not stated] as an anticoagulant for haemodialysis. The woman experienced nausea, vomiting, sweating, chest oppression and abdominal pain immediately after the start of haemodialysis using nafamostat. Her BP fell to 50mm Hg by palpation. Haemodialysis was stopped because an anaphylactoid reaction to nafamostat was suspected. She was treated with hydrocortisone, an isotonic sodium chloride solution, norepinephrine [noradrenaline] and human serum albumin. The woman’s symptoms persisted for 5 hours before gradually subsiding. After her BP had normalised, ultrafiltration was started with dalteparin sodium and she did not experience any further anaphylactoid reactions. Approximately 3 weeks earlier, she had experienced nausea and vomiting a few minutes after the start of haemodialysis with nafamostat; however, on this occasion haemodialysis had not been stopped. Author comment: Nafamostat seems to be the most likely precipitant of the anaphylactoid reaction that occurred in this patient. ‘This report describes the first case of an anaphylactoid reaction induced by Futhan as an anticoagulant in a hemodialysis patient.’ Maruyama H, et al. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron 74: 468-469, Oct 1996 - Japan 800486153 1 Reactions 7 Dec 1996 No. 630 0114-9954/10/0630-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Nafamostat
Reactions 630 - 7 Dec 1996
★ SNafamostat
First report of an anaphylactoid reaction: casereport
An anaphylactoid reaction occurred in a 53-year-old womanafter she received nafamostat [Futhan®; dosage not stated] asan anticoagulant for haemodialysis.
The woman experienced nausea, vomiting, sweating, chestoppression and abdominal pain immediately after the start ofhaemodialysis using nafamostat. Her BP fell to 50mm Hg bypalpation. Haemodialysis was stopped because ananaphylactoid reaction to nafamostat was suspected. She wastreated with hydrocortisone, an isotonic sodium chloridesolution, norepinephrine [noradrenaline] and human serumalbumin.
The woman’s symptoms persisted for 5 hours beforegradually subsiding. After her BP had normalised, ultrafiltrationwas started with dalteparin sodium and she did not experienceany further anaphylactoid reactions.
Approximately 3 weeks earlier, she had experienced nauseaand vomiting a few minutes after the start of haemodialysiswith nafamostat; however, on this occasion haemodialysis hadnot been stopped.
Author comment: Nafamostat seems to be the most likelyprecipitant of the anaphylactoid reaction that occurred in thispatient. ‘This report describes the first case of an anaphylactoidreaction induced by Futhan as an anticoagulant in ahemodialysis patient.’Maruyama H, et al. Anaphylactoid reaction induced by nafamostat mesilate in ahemodialysis patient. Nephron 74: 468-469, Oct 1996 - Japan 800486153
1
Reactions 7 Dec 1996 No. 6300114-9954/10/0630-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
